Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats

Chemical Research in Toxicology

Volumn 21, Issue 12, 2008, Pages 2260-2271

  Dalvie, Deepak ^a   Kang, Ping ^a   Zientek, Michael ^a   Xiang, Cathie ^a   Zhou, Sue ^a   Obach, R Scott ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; LIVER PROTEIN; RALOXIFENE;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INTESTINE; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MICROSOME; NONHUMAN; OXIDATION; RAT;

ANIMALS; BIOTRANSFORMATION; BONE DENSITY CONSERVATION AGENTS; GLUCURONIDES; HUMANS; INTESTINES; LIVER; MICROSOMES, LIVER; RALOXIFENE; RATS; SPECIES SPECIFICITY;

RATTUS;

EID: 58149103921     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800323w     Document Type: Article

References (35)

1. Heringa, M. (2003) Review on raloxifene profile of selective estrogen receptor modulator. Int. J. Clin. Pharmacol. Ther. 41, 331-345.
2. Felson, D. T., Zhang, Y., Hannan, M., Keil, D. P., Wilson, P. W. F., and Anderson, J. J. (1993) The effect of post-menopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329, 1141-1146.
3. Jones, C. D., Jevinkar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., and Clemens, J. A. (1984) Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzothiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]3yl] [4-[2-(1-piperidinyl)ethoxylphenyl)methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27, 1057-1066.
4. Kelminski, A. (2002) The study of tamoxifen and raloxifene (STAR Trial) for the prevention of breast cancer. Hawaii Med. J. 61, 209-210.
5. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene Irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
6. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., van Breemen, R. B., Thatcher, G. R. J., and Bolton, J. L. (2004) Oxidation of raloxifene to quinoids: Potential toxic pathways via a diquinone methide and o-quinones. Chem. Res. Toxicol. 17, 879-888.
7. Baer, B. R., Wienkers, L. C., and Rock, D. A. (2007) Time-dependent inactivation of P450 3A4 by raloxifene identification of Cys239 as the site of apoprotein alkylation. Chem. Res. Toxicol. 20, 954-964.
8. Liu, J., Li, Q., Yang, X., Van Breemen, R. B., Bolton, J. L., and Thatcher, G. R. J. (2005) Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag raloxifene proof-of-principle study. Chem. Res. Toxicol. 18, 1485-1496.
9. Snyder, K. R., Sparano, N., and Malinowski, J. M. (2000) Raloxifene hydrochloride. Am. J. Health-Syst. Pharm. 57, 1669-1678.
10. Morrello, K. C., Wurz, G. T., and DeGregorio, M. W. (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42, 361-372.
11. Hochner-Celnikier, D. (1999) Pharmacokinetics of raloxifene and its clinical applications. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 23-29.
12. 14C]- raloxifene in humans. Pharm. Res. 12, S-372.
13. Lindstrom, T. D., Whitaker, N. G., and Whitaker, G. W. (1984) Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 14, 841-847.
14. Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., MacIntyre, F., Rance, D. J., and Wastall, P. (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283, 46-58.
15. Obach, R. S. (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27, 1350-1359.
16. Obach, R. S. (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr. Opin. Drug Discovery Dev. 4, 36-44.
17. Mohutsky, M. A., Chien, J. Y., Ring, B. J., and Wrighton, S. A. (2006) Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase i and phase ii biotransformations. Pharmacol. Res. 23, 654-662.
18. Obach, R. S., and Reed-Hagen, A. E. (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab. Dispos. 30, 831-837.
19. De Buck, S. E., and Mackie, C. E. (2007) Physiologically based approaches towards the prediction of pharmacokinetics in vivo and in vitro extrapolation. Exp. Opin. Drug Metab. Toxicol. 3, 865-878.
20. Jeong, E. J., Liu, Y., Lin, H., and Hu, M. (2005) Species- and disposition model-dependent metabolism of raloxifene in gut and liver role of UGT1A10. Drug Metab. Dispos. 33, 785-794.
21. Kemp, D. C., Fan, P. W., and Stevens, J. C. (2002) Characterization of raloxifene glucuronidation in vitro. Contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30, 694-700.
22. Strassburg, C. P., Nguyen, N., Manns, M. P., and Tukey, R. H. (1999) UDP-glucurononyltransferase activity in human liver and colon. Gastroenterology 116, 149-160.
23. Tukey, R. H., and Strassburg, C. P. (2000) Human UDP- glucuronoyltransferases metabolism, expression and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616.
24. Chiba, M., Hensleigh, M, and Lin, J. H. (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem. Pharmacol. 53, 1187-1195.
25. Custodio, J. M., Wu, C.-Y., and Benet, L. Z. (2008) Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Delivery Rev. 60, 717-733.
26. Bergström, C. A. S. (2005) Computational models to predict aqueous drug solubility permeability and intestinal absorption. Exp. Opin. Drug Metab. Toxicol. 1, 613-627.
27. Chang, J. H., Kochansky, C. J., and Shou, M. (2006) The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab. Dispos. 34, 2073-2078.
28. Lin, J. H., Chiba, M., and Baillie, T. A. (1999) Is the role of the small intestine in the first pass metabolism overemphasized? Pharmacol. Rev. 51, 135-157.
29. Rostami-Hodjegan, A., and Tucker, G. T. (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technol. 1, 441-448.
30. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
31. Kalgutkar, A. S., and Soglia, J. R. (2005) Minimizing the potential for metabolic activation in drug discovery. Exp. Opin. Drug Metab. Toxicol. 1, 91-141.
32. Baillie, T. A. (2006) Future of toxicology - Metabolic activation and drug design: Challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19, 889-893.
33. Baillie, T. A. (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129-137.
34. Kumar, S., Kassahun, K., Tschirret-Guth, R. A., Mitra, K., and Baillie, T. A. (2008) Minimizing metabolic activation during pharmaceutical lead optimization: Progress, knowledge gaps and future directions. Curr. Opin. Drug Discovery Dev. 11, 43-52.
35. Doss, G. A., and Baillie, T. A. (2006) Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 38, 641-649.